- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..
Valeant is selling its Australian unit iNova to raise $930 million to pay down debt.
Stocks significantly pared losses by the end of the session, though still ended slightly lower.